Immunization, Passive

• 

  Subject Areas on Research

  • A fatal case of coronavirus disease 2019 in a patient with common variable immunodeficiency. 
  • A program for eradication of hepatitis B from Taiwan by a 10-year, four-dose vaccination program. 
  • A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. 
  • A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. 
  • APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice. 
  • Absence of macrophage involvement in the passive serum therapy of Friend leukemia virus-induced disease. 
  • Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. 
  • Acute hemolysis in a patient with cytomegalovirus pneumonitis treated with intravenous immunoglobulin (IVIG). 
  • Adoptively transferred immunity persists in human marrow graft recipients. 
  • Advances in the diagnosis and treatment of primary immunodeficiency diseases. 
  • Alloimmune thrombocytopenia may be associated with systemic disease. 
  • Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. 
  • Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. 
  • Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. 
  • Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease. 
  • Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. 
  • Antibody alone does not prevent experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency (MAIDS). 
  • Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development? 
  • Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. 
  • Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors. 
  • Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. 
  • Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma. 
  • Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. 
  • Bronchiolitis. 
  • COVID-19 convalescent plasma. 
  • COVID-19 convalescent plasma: Interim recommendations from the AABB. 
  • COVID19 antibody detection using lateral flow assay tests in a cohort of convalescent plasma donors. 
  • Catch those antibodies before they fall. 
  • Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. 
  • Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. 
  • Chronic norovirus infection in primary immune deficiency disorders: an international case series. 
  • Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma. 
  • Clinical immunotherapy for brain tumors. 
  • Comparison of active and combined passive/active immunization of Navajo children against Haemophilus influenzae type b. 
  • Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. 
  • Cytomegalovirus Screening in Pregnancy: A Cost-Effectiveness and Threshold Analysis. 
  • D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. 
  • Dengue vascular leakage is augmented by mast cell degranulation mediated by immunoglobulin Fcγ receptors. 
  • Deployment of convalescent plasma for the prevention and treatment of COVID-19. 
  • Diagnosis and antenatal management of congenital cytomegalovirus infection. 
  • Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. 
  • Effective antibody therapy in herpes simplex virus ocular infection. Characterization of recipient immune response. 
  • Effects of donor splenocytes treated with mitomycin C on rat hepatic, cardiac, and intestinal allografts. 
  • Efficacy of immune therapy in early experimental Naegleria fowleri meningitis. 
  • Elimination of mycoplasma from human B-lymphoblastoid cell lines. 
  • Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. 
  • Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. 
  • Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. 
  • Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. 
  • Graft-versus-leukemia in man: relationship of acute and chronic graft-versus-host disease to relapse of acute leukemia following allogeneic bone marrow transplantation. 
  • Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. 
  • Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. VI. Evidence for different T cell receptors in cells that mediate H-21-restricted and H-2D-restricted cutaneous sensitivity responses. 
  • How did we rapidly implement a convalescent plasma program? 
  • Human T cells specifically activated against autologous malignant melanoma. 
  • Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells. 
  • Hyperimmune human IgG or recombinant human granulocyte-macrophage colony-stimulating factor as adjunctive therapy for group B streptococcal sepsis in newborn rats. 
  • Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. 
  • Immunobiology of human gliomas. 
  • Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. 
  • Immunoglobulin therapy in bone marrow transplantation. 
  • Immunologic control of a retrovirus-associated murine adenocarcinoma. VI. Augmentation of antibody-dependent killing following quantitative and qualitative changes in host peritoneal cells. 
  • Immunologic control of a retrovirus-associated murine adenocarcinoma. VII. Tumor cell destruction by macrophages and IgG2A. 
  • Immunologic control of the ascites form of murine adenocarcinoma 755. II. Tumor immunity associated with a Friend--Moloney--Ra,scher-type virus. 
  • Immunologic control of the ascites form of murine adenocarcinoma 755. III. Efficacy of serum therapy is controlled by a single genetic locus. 
  • Immunologic control of the ascites form of murine adenocarcinoma 755. IV. Characterization of the protective antibody in hyperimmune serum. 
  • Immunologic control of the ascites of murine adenocarcinoma 755. I. Protection with syngeneic immune serum or lymphoid cells. 
  • Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. 
  • Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor. 
  • Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. 
  • Immunotherapy of a murine leukemia virus-infected, chemically induced murine sarcoma with antiviral antibodies. 
  • Immunotherapy of murine leukemia. II. Effect of passive serum therapy on Friend murine leukemia virus-induced hematologic and coagulation parameters. 
  • Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. 
  • Immunotherapy of surgical malignancies. 
  • In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. 
  • Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but Broadly Protective Viral Epitope. 
  • Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. 
  • Intravenous immune globulin prophylaxis in recipients of a marrow transplant. 
  • Localization of a domain in the FimH adhesin of Escherichia coli type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection. 
  • Localization of functionally different guinea-pig spleen cells in albumin gradients. 
  • Long-term ethanol consumption alters the hepatic response to the regenerative effects of tumor necrosis factor-alpha. 
  • Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. 
  • Maternal gatekeepers: How maternal antibody Fc characteristics influence passive transfer and infant protection. 
  • Medical treatment of patients with infantile spasms. 
  • Molecular mechanisms of pathogenesis. 
  • Monoclonal antibodies for brain tumour treatment. 
  • Neutralizing antibodies take a swipe at HIV in vivo. 
  • Nosocomial hepatitis A infection in a paediatric intensive care unit. 
  • Outcomes of COVID-19 in patients with CLL: a multicenter international experience. 
  • Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults. 
  • Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission? 
  • Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. 
  • Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. 
  • Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. 
  • Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia. 
  • Passive transfer of human myasthenia gravis to rats: 1. Electrophysiology of the developing neuromuscular block. 
  • Pathogenesis of autoimmunity in pemphigus. 
  • Pediatric anthrax: implications for bioterrorism preparedness. 
  • Persistence of Campylobacter fetus bacteremia associated with absence of opsonizing antibodies. 
  • Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. 
  • Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. 
  • Polyclonal HIV envelope-specific breast milk antibodies limit founder SHIV acquisition and cell-associated virus loads in infant rhesus monkeys. 
  • Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. 
  • Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. 
  • Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. 
  • Potential Confounding of Diagnosis of Rabies in Patients with Recent Receipt of Intravenous Immune Globulin. 
  • Preoperative preparation of patients with myasthenia gravis forestalls postoperative respiratory complications after thymectomy. 
  • Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors. 
  • Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. 
  • Prevention of oncornavirus-induced sarcomas in cats by treatment with antiviral antibodies. 
  • Primary Immune Deficiency: Patients' Preferences for Replacement Immunoglobulin Therapy. 
  • Properties of mouse leukemia viruses. XIII. Serum therapy of virus-induced murine leukemias. 
  • Properties of mouse leukemia viruses. XVII. Factors required for successful treatment of spontaneous AKR leukemia by antibodies against gp71. 
  • Properties of mouse leukemia viruses: XX. Variation of AKR Substrains in response to antibody therapy. 
  • Prospects for treatment of human retrovirus-associated diseases. 
  • Protection of mice from Semliki Forest virus infection by lymphocytes treated with low levels of interferon. 
  • Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. 
  • Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. 
  • Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules. 
  • Relapse in Guillain-Barré syndrome after treatment with human immune globulin. 
  • Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. 
  • Rh immune globulin prophylaxis for threatened abortions. 
  • Role of antibodies to murine leukemia virus p15E transmembrane protein in immunotherapy against AKR leukemia: a model for studies in human acquired immunodeficiency syndrome. 
  • SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. 
  • Safety and varicella outcomes after varicella zoster immune globulin administration in pregnancy. 
  • Seroconversion for hepatitis C virus antibody in bone marrow recipients treated with immune globulin. 
  • Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial. 
  • Stage II malignant melanoma: presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients. 
  • Structural basis for the proinflammatory cytokine activity of high mobility group box 1. 
  • Subcutaneous immunoglobulin replacement therapy with Hizentra® is safe and effective in two infants. 
  • Successful treatment of autoimmune hemolytic anemia in common variable immunodeficiency with high-dose intravenous gamma globulin. 
  • Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. 
  • Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses. 
  • Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization. 
  • Tetanus neonatorum: clinico-epidemiological profile. 
  • The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. 
  • The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients. 
  • The effects of leukemosuppressive immunotherapy on bone marrow infectious cell centers in AKR mice. 
  • The quest for an antibody-based HIV vaccine. 
  • The relationship of complement consumption to immune fever. 
  • The role of RT1.a major histocompatibility antigens in prolonging the survival of hepatic allografts in the rat. 
  • The role of bone marrow and thymic elements in the initiation and spread of virus production in the AKR thymus. 
  • The role of class I major histocompatibility complex antigens in prolonging the survival of hepatic allografts in the rat. 
  • The use of intravenous immune globulin in immunodeficiency diseases. 
  • Therapeutic CD154 antibody for lupus: promise for the future? 
  • Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. 
  • Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. 
  • Transfer of specific immunity in marrow recipients given HLA-mismatched, T cell-depleted, or HLA-identical marrow grafts. 
  • Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2. 
  • Treatment of intracranial alphavirus infections in mice by a combination of specific antibodies and an interferon inducer. 
  • Use of a new chemically modified intravenous IgG preparation in severe primary humoral immunodeficiency: clinical efficacy and attempts to individualize dosage. 
  • Use of donor serum to prevent passive transfer of hyperacute rejection. 
  • Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial. 
  • Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. 
  • XVIII. Effective treatment of AKR leukemia with antibody to gp7 1 eliminates the neonatal burst of ecotropic AKR virus producing cells. 
• 

  Keywords of People

  • Buckley, Rebecca Hatcher, James Buren Sidbury Distinguished Professor Emeritus of Pediatrics, in the School of Medicine, Pediatrics, Allergy and Immunology